Abstract
FDG PET allows one to study in vivo tissue metabolism, and thus to demonstrate malignant tumors as hypermetabolic lesions, showing an increase of tracer uptake. At present 18F radiolabelled fluorodeoxyglucose (FDG) is the most employed compound in the clinical practice. Cancer cells are known to have increased anaerobial glycolytic activity and higher expression of glucose transporters. Many papers have demonstrated a relevant impact of FDG PET on staging of many neoplastic diseases, and a better accuracy of FDG PET in comparison with conventional diagnostic methods for therapy response evaluation and for relapse identification in many cancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2009). PET-CT in Oncology. In: Atlas of PET/CT - A Quick Guide to Image Interpretation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77772-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-540-77772-4_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-77771-7
Online ISBN: 978-3-540-77772-4
eBook Packages: MedicineMedicine (R0)